[go: up one dir, main page]

MX2018011035A - Anticuerpos-anti-mica. - Google Patents

Anticuerpos-anti-mica.

Info

Publication number
MX2018011035A
MX2018011035A MX2018011035A MX2018011035A MX2018011035A MX 2018011035 A MX2018011035 A MX 2018011035A MX 2018011035 A MX2018011035 A MX 2018011035A MX 2018011035 A MX2018011035 A MX 2018011035A MX 2018011035 A MX2018011035 A MX 2018011035A
Authority
MX
Mexico
Prior art keywords
mica
mica antibodies
binding proteins
antigen
binding
Prior art date
Application number
MX2018011035A
Other languages
English (en)
Inventor
Blery Mathieu
Gauthier Laurent
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2018011035A publication Critical patent/MX2018011035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)

Abstract

La presente invención proporciona proteínas de unión a antígeno capaces de unirse a polipéptidos MICA humanos. Las proteínas de unión a antígeno tienen una actividad aumentada en el tratamiento de trastornos caracterizados por células que expresan MICA, particularmente cáncer.
MX2018011035A 2016-03-15 2017-03-14 Anticuerpos-anti-mica. MX2018011035A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308443P 2016-03-15 2016-03-15
PCT/EP2017/055920 WO2017157895A1 (en) 2016-03-15 2017-03-14 Anti-mica antibodies

Publications (1)

Publication Number Publication Date
MX2018011035A true MX2018011035A (es) 2019-01-17

Family

ID=58314189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011035A MX2018011035A (es) 2016-03-15 2017-03-14 Anticuerpos-anti-mica.

Country Status (12)

Country Link
US (1) US20170267764A1 (es)
EP (1) EP3430047A1 (es)
JP (1) JP2019517993A (es)
KR (1) KR20180118673A (es)
CN (1) CN108779178A (es)
AU (1) AU2017235274A1 (es)
BR (1) BR112018068678A2 (es)
CA (1) CA3016765A1 (es)
MX (1) MX2018011035A (es)
RU (1) RU2018128215A (es)
SG (1) SG11201806542PA (es)
WO (1) WO2017157895A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201404177PA (en) 2012-02-07 2014-08-28 Innate Pharma Mica binding agents
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
JP2019535250A (ja) * 2016-10-29 2019-12-12 ジェネンテック， インコーポレイテッド 抗ｍｉｃ抗体及び使用方法
US20200023071A1 (en) * 2017-02-06 2020-01-23 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
CL2017003503A1 (es) * 2017-12-29 2018-06-01 Univ Chile Anticuerpo humano y fragmentos de este, para ser utilizados en el tratamiento del cáncer gástrico (cg) y eventualmente otro tipo de tumores que expresen la proteína mica (del inglés “mhc class i chain-related gene a).
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CN119930819A (zh) 2018-07-31 2025-05-06 库利南Mica公司 阻断mica/b脱落的抗mica/b抗体及其使用方法
WO2020035345A1 (en) * 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
AU2019408408A1 (en) 2018-12-21 2021-06-03 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
CN110903402B (zh) * 2019-11-27 2023-02-28 中国药科大学 一种双特异性融合蛋白及其构建方法与应用
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN112574311B (zh) * 2020-12-14 2022-03-25 广州康盛生物科技股份有限公司 双mic结合活性的抗体及其应用
CN118660964A (zh) 2021-12-16 2024-09-17 瓦莱里奥治疗公司 新型缀合核酸分子及其用途
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114657123B (zh) * 2022-03-09 2023-07-04 重庆医科大学附属儿童医院 白血病特异性树突状细胞来源的过表达rae-1的外泌体无细胞疫苗及其制备方法
US20250368742A1 (en) * 2022-04-08 2025-12-04 D2M Biotherapeutics Limited Anti-mica/b antibodies and uses thereof
CN120965880A (zh) * 2022-08-02 2025-11-18 广州康盛生物科技股份有限公司 一种抗mic的人源化单链抗体、免疫吸附剂及其用途
CN118684776B (zh) * 2024-07-02 2025-10-28 常州费洛斯药业科技有限公司 一种靶向mica的全人源抗体或抗体片段及其嵌合抗原受体和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
WO2004103269A2 (en) 2002-10-18 2004-12-02 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005115452A2 (en) 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
AU2005244058B2 (en) 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
CA2618681C (en) 2005-08-10 2015-10-27 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
NZ596322A (en) 2006-01-17 2013-02-22 Synthon Biopharmaceuticals Bv Compositions and methods for humanization and optimization of N-glycans in duckweed plants
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
LT2542256T (lt) 2010-03-04 2019-10-25 Macrogenics Inc Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
MY162489A (en) 2010-12-23 2017-06-15 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
PE20142361A1 (es) * 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
SG11201404177PA (en) * 2012-02-07 2014-08-28 Innate Pharma Mica binding agents

Also Published As

Publication number Publication date
WO2017157895A1 (en) 2017-09-21
CA3016765A1 (en) 2017-09-21
KR20180118673A (ko) 2018-10-31
BR112018068678A2 (pt) 2019-01-15
EP3430047A1 (en) 2019-01-23
CN108779178A (zh) 2018-11-09
AU2017235274A1 (en) 2018-08-16
JP2019517993A (ja) 2019-06-27
US20170267764A1 (en) 2017-09-21
SG11201806542PA (en) 2018-08-30
RU2018128215A (ru) 2020-04-15

Similar Documents

Publication Publication Date Title
MX2018011035A (es) Anticuerpos-anti-mica.
CY1125327T1 (el) Anti-pd-1 αντισωματα και συνθεσεις
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CY1123256T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
CL2018003378A1 (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno.
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
EP3442577A4 (en) TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST TRANSLATION MODIFIED ANTI-VEGF FAB
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
CU24498B1 (es) Anticuerpos de factor xi
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201591762A1 (ru) Человеческие антитела к grem1
EA201690898A1 (ru) Способы лечения таупатии
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX393740B (es) Anticuerpos contra alfa-sinucleina y sus usos.